Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Prostatic Neoplasms | 187 | 2024 | 1721 | 28.220 |
Why?
|
Testicular Neoplasms | 34 | 2023 | 105 | 12.180 |
Why?
|
Prostatectomy | 68 | 2022 | 471 | 11.900 |
Why?
|
Prostate-Specific Antigen | 54 | 2024 | 353 | 11.880 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 20 | 2023 | 47 | 7.230 |
Why?
|
Prostate | 40 | 2023 | 378 | 7.010 |
Why?
|
Kidney Neoplasms | 37 | 2021 | 621 | 5.750 |
Why?
|
Lymph Node Excision | 23 | 2023 | 217 | 5.520 |
Why?
|
Watchful Waiting | 15 | 2023 | 60 | 5.320 |
Why?
|
Nephrectomy | 32 | 2021 | 294 | 5.050 |
Why?
|
Male | 279 | 2024 | 40965 | 4.700 |
Why?
|
Neoplasm Grading | 28 | 2023 | 357 | 3.890 |
Why?
|
Carcinoma, Renal Cell | 20 | 2021 | 426 | 3.460 |
Why?
|
Early Detection of Cancer | 18 | 2024 | 394 | 3.330 |
Why?
|
Humans | 301 | 2024 | 86643 | 3.240 |
Why?
|
Neoplasm Staging | 54 | 2023 | 1939 | 2.790 |
Why?
|
Laser Therapy | 12 | 2020 | 142 | 2.400 |
Why?
|
Neoplasm Recurrence, Local | 21 | 2023 | 1313 | 2.390 |
Why?
|
Robotic Surgical Procedures | 8 | 2022 | 267 | 2.350 |
Why?
|
Magnetic Resonance Imaging, Interventional | 9 | 2020 | 36 | 2.350 |
Why?
|
Retroperitoneal Space | 14 | 2023 | 38 | 2.290 |
Why?
|
Population Surveillance | 7 | 2019 | 219 | 2.220 |
Why?
|
Magnetic Resonance Imaging | 37 | 2023 | 3362 | 2.170 |
Why?
|
Aged | 112 | 2023 | 18415 | 2.170 |
Why?
|
Urinary Incontinence | 9 | 2017 | 206 | 2.120 |
Why?
|
Seminoma | 4 | 2023 | 10 | 2.090 |
Why?
|
Biopsy | 32 | 2023 | 1163 | 2.080 |
Why?
|
Laparoscopy | 20 | 2018 | 754 | 2.070 |
Why?
|
Middle Aged | 126 | 2021 | 25028 | 2.050 |
Why?
|
Biomarkers, Tumor | 19 | 2024 | 1464 | 2.000 |
Why?
|
Image-Guided Biopsy | 12 | 2023 | 66 | 1.880 |
Why?
|
Mass Screening | 11 | 2023 | 618 | 1.840 |
Why?
|
Ablation Techniques | 5 | 2019 | 34 | 1.820 |
Why?
|
Lymph Nodes | 7 | 2019 | 533 | 1.790 |
Why?
|
SEER Program | 9 | 2020 | 190 | 1.780 |
Why?
|
Adenocarcinoma | 5 | 2023 | 1169 | 1.780 |
Why?
|
Prognosis | 37 | 2023 | 3679 | 1.730 |
Why?
|
Life Expectancy | 4 | 2017 | 86 | 1.690 |
Why?
|
Retrospective Studies | 61 | 2023 | 8489 | 1.690 |
Why?
|
Orchiectomy | 10 | 2018 | 68 | 1.640 |
Why?
|
Teratoma | 6 | 2023 | 50 | 1.590 |
Why?
|
Chemotherapy, Adjuvant | 7 | 2022 | 468 | 1.520 |
Why?
|
Urology | 6 | 2023 | 110 | 1.480 |
Why?
|
Organ Transplantation | 4 | 2020 | 265 | 1.460 |
Why?
|
Retroperitoneal Neoplasms | 5 | 2018 | 43 | 1.460 |
Why?
|
Quality of Life | 12 | 2022 | 1585 | 1.430 |
Why?
|
Patient Selection | 13 | 2021 | 685 | 1.420 |
Why?
|
Practice Guidelines as Topic | 8 | 2021 | 1036 | 1.370 |
Why?
|
Treatment Outcome | 48 | 2023 | 7993 | 1.350 |
Why?
|
Disease Management | 5 | 2019 | 327 | 1.340 |
Why?
|
Lymphatic Metastasis | 16 | 2020 | 486 | 1.330 |
Why?
|
Photochemotherapy | 7 | 2018 | 97 | 1.310 |
Why?
|
Risk Assessment | 31 | 2023 | 2261 | 1.290 |
Why?
|
Robotics | 12 | 2015 | 267 | 1.290 |
Why?
|
Consensus | 11 | 2020 | 335 | 1.290 |
Why?
|
Biopsy, Needle | 14 | 2014 | 235 | 1.270 |
Why?
|
Kallikreins | 7 | 2020 | 47 | 1.240 |
Why?
|
United States | 31 | 2020 | 6672 | 1.220 |
Why?
|
Warm Ischemia | 5 | 2014 | 28 | 1.110 |
Why?
|
Cryosurgery | 7 | 2018 | 41 | 1.090 |
Why?
|
Radiotherapy, Adjuvant | 6 | 2017 | 292 | 1.070 |
Why?
|
Risk Factors | 26 | 2023 | 5417 | 1.060 |
Why?
|
Adult | 59 | 2023 | 25648 | 1.030 |
Why?
|
Incidence | 18 | 2022 | 1577 | 1.010 |
Why?
|
Ultrasound, High-Intensity Focused, Transrectal | 5 | 2012 | 6 | 0.980 |
Why?
|
Salvage Therapy | 6 | 2017 | 233 | 0.970 |
Why?
|
Practice Patterns, Physicians' | 5 | 2020 | 582 | 0.960 |
Why?
|
Surgery, Computer-Assisted | 5 | 2018 | 99 | 0.950 |
Why?
|
Kidney | 10 | 2021 | 1241 | 0.950 |
Why?
|
Urinary Bladder Neoplasms | 10 | 2021 | 383 | 0.910 |
Why?
|
Combined Modality Therapy | 13 | 2020 | 1686 | 0.910 |
Why?
|
Epididymis | 6 | 2018 | 18 | 0.910 |
Why?
|
Predictive Value of Tests | 22 | 2018 | 1673 | 0.890 |
Why?
|
Cohort Studies | 21 | 2022 | 2767 | 0.870 |
Why?
|
Disease-Free Survival | 14 | 2018 | 1204 | 0.850 |
Why?
|
Prospective Studies | 25 | 2023 | 4213 | 0.850 |
Why?
|
Neoplasm Invasiveness | 13 | 2016 | 552 | 0.820 |
Why?
|
Erectile Dysfunction | 3 | 2014 | 74 | 0.800 |
Why?
|
Logistic Models | 10 | 2023 | 1186 | 0.790 |
Why?
|
Tumor Burden | 7 | 2021 | 289 | 0.790 |
Why?
|
Carcinoma, Transitional Cell | 7 | 2021 | 164 | 0.780 |
Why?
|
Proportional Hazards Models | 13 | 2022 | 859 | 0.780 |
Why?
|
Glomerular Filtration Rate | 8 | 2014 | 384 | 0.780 |
Why?
|
Aged, 80 and over | 24 | 2020 | 6509 | 0.760 |
Why?
|
Seminal Vesicles | 5 | 2022 | 39 | 0.760 |
Why?
|
Postoperative Complications | 9 | 2020 | 2207 | 0.730 |
Why?
|
Age Factors | 13 | 2017 | 1851 | 0.710 |
Why?
|
Terminology as Topic | 2 | 2021 | 217 | 0.700 |
Why?
|
Induction Chemotherapy | 1 | 2020 | 147 | 0.690 |
Why?
|
Rectum | 3 | 2018 | 146 | 0.680 |
Why?
|
Genes, Neoplasm | 1 | 2019 | 37 | 0.680 |
Why?
|
Lost to Follow-Up | 1 | 2018 | 12 | 0.670 |
Why?
|
Clinical Protocols | 2 | 2019 | 156 | 0.660 |
Why?
|
Aorta, Abdominal | 1 | 2018 | 60 | 0.650 |
Why?
|
Intraoperative Complications | 2 | 2018 | 185 | 0.650 |
Why?
|
Time Factors | 22 | 2018 | 5210 | 0.650 |
Why?
|
Multivariate Analysis | 14 | 2018 | 999 | 0.650 |
Why?
|
Guideline Adherence | 3 | 2016 | 223 | 0.640 |
Why?
|
Insurance, Health | 2 | 2017 | 160 | 0.640 |
Why?
|
Acinar Cells | 1 | 2017 | 6 | 0.610 |
Why?
|
Postoperative Hemorrhage | 2 | 2016 | 46 | 0.610 |
Why?
|
alpha-Fetoproteins | 1 | 2017 | 45 | 0.590 |
Why?
|
Pathologists | 1 | 2017 | 24 | 0.590 |
Why?
|
Vena Cava, Inferior | 1 | 2018 | 143 | 0.590 |
Why?
|
Androgen Antagonists | 3 | 2024 | 144 | 0.590 |
Why?
|
Neoplasms | 2 | 2022 | 2898 | 0.570 |
Why?
|
Public Policy | 1 | 2016 | 52 | 0.570 |
Why?
|
Cold Ischemia | 2 | 2014 | 17 | 0.570 |
Why?
|
Platelet Aggregation Inhibitors | 2 | 2022 | 134 | 0.570 |
Why?
|
Biomarkers | 6 | 2021 | 1718 | 0.560 |
Why?
|
Minimally Invasive Surgical Procedures | 4 | 2014 | 237 | 0.560 |
Why?
|
Anti-Bacterial Agents | 2 | 2013 | 746 | 0.550 |
Why?
|
Survival Rate | 11 | 2015 | 1863 | 0.550 |
Why?
|
Carcinoma, Ductal | 1 | 2015 | 18 | 0.540 |
Why?
|
Carcinoma, Acinar Cell | 1 | 2015 | 11 | 0.540 |
Why?
|
Medically Uninsured | 1 | 2015 | 58 | 0.540 |
Why?
|
Young Adult | 12 | 2020 | 5976 | 0.530 |
Why?
|
Medicare | 2 | 2020 | 410 | 0.530 |
Why?
|
Aspirin | 1 | 2016 | 156 | 0.520 |
Why?
|
Conversion to Open Surgery | 1 | 2015 | 11 | 0.520 |
Why?
|
Immunosuppressive Agents | 1 | 2020 | 977 | 0.520 |
Why?
|
Goserelin | 1 | 2014 | 6 | 0.510 |
Why?
|
Health Policy | 1 | 2016 | 180 | 0.510 |
Why?
|
Tosyl Compounds | 1 | 2014 | 15 | 0.510 |
Why?
|
Contrast Media | 12 | 2019 | 1078 | 0.510 |
Why?
|
Cost-Benefit Analysis | 1 | 2017 | 454 | 0.500 |
Why?
|
Surgeons | 1 | 2018 | 238 | 0.500 |
Why?
|
Carboplatin | 1 | 2015 | 286 | 0.490 |
Why?
|
Anilides | 1 | 2014 | 47 | 0.490 |
Why?
|
Kidney Diseases | 3 | 2010 | 418 | 0.490 |
Why?
|
Nitriles | 1 | 2014 | 149 | 0.480 |
Why?
|
Gonadotropin-Releasing Hormone | 1 | 2014 | 103 | 0.480 |
Why?
|
Ciprofloxacin | 1 | 2013 | 29 | 0.460 |
Why?
|
Intestinal Diseases | 1 | 2014 | 79 | 0.460 |
Why?
|
Decision Making | 2 | 2022 | 642 | 0.460 |
Why?
|
Databases, Factual | 6 | 2016 | 814 | 0.450 |
Why?
|
Androgens | 5 | 2024 | 167 | 0.450 |
Why?
|
Brachytherapy | 5 | 2017 | 119 | 0.450 |
Why?
|
Survival Analysis | 13 | 2019 | 1538 | 0.440 |
Why?
|
Follow-Up Studies | 16 | 2022 | 3640 | 0.440 |
Why?
|
Female | 46 | 2023 | 44532 | 0.430 |
Why?
|
Nomograms | 3 | 2011 | 28 | 0.430 |
Why?
|
Expert Testimony | 3 | 2020 | 46 | 0.430 |
Why?
|
Developed Countries | 1 | 2012 | 24 | 0.430 |
Why?
|
Sensitivity and Specificity | 12 | 2019 | 1991 | 0.420 |
Why?
|
Developing Countries | 1 | 2012 | 71 | 0.410 |
Why?
|
Neoplasm, Residual | 7 | 2023 | 162 | 0.400 |
Why?
|
High-Intensity Focused Ultrasound Ablation | 4 | 2020 | 40 | 0.400 |
Why?
|
Clinical Trials as Topic | 5 | 2019 | 1169 | 0.400 |
Why?
|
Global Health | 1 | 2012 | 193 | 0.380 |
Why?
|
Feasibility Studies | 6 | 2022 | 751 | 0.380 |
Why?
|
Epithelial Cells | 5 | 2018 | 669 | 0.380 |
Why?
|
Forecasting | 3 | 2019 | 304 | 0.380 |
Why?
|
Finasteride | 2 | 2009 | 8 | 0.370 |
Why?
|
Sentinel Surveillance | 1 | 2009 | 23 | 0.360 |
Why?
|
Kidney Tubules, Collecting | 1 | 2009 | 23 | 0.350 |
Why?
|
Environmental Exposure | 1 | 2012 | 296 | 0.350 |
Why?
|
Sus scrofa | 1 | 2009 | 45 | 0.350 |
Why?
|
Treatment Failure | 2 | 2014 | 285 | 0.350 |
Why?
|
Systems Theory | 1 | 2009 | 2 | 0.350 |
Why?
|
5-alpha Reductase Inhibitors | 1 | 2009 | 7 | 0.350 |
Why?
|
Gadolinium DTPA | 7 | 2014 | 261 | 0.340 |
Why?
|
Bucrylate | 1 | 2008 | 2 | 0.340 |
Why?
|
Sutures | 1 | 2009 | 52 | 0.340 |
Why?
|
Disease Progression | 10 | 2018 | 1531 | 0.340 |
Why?
|
Tissue Adhesives | 1 | 2008 | 23 | 0.340 |
Why?
|
Breast Neoplasms | 1 | 2022 | 2903 | 0.330 |
Why?
|
Hospitalization | 1 | 2014 | 849 | 0.330 |
Why?
|
Chemoprevention | 1 | 2009 | 91 | 0.330 |
Why?
|
Enzyme Inhibitors | 2 | 2009 | 639 | 0.330 |
Why?
|
Research Design | 3 | 2019 | 594 | 0.320 |
Why?
|
Tomography, X-Ray Computed | 8 | 2019 | 2601 | 0.320 |
Why?
|
Image Enhancement | 4 | 2018 | 563 | 0.320 |
Why?
|
Kaplan-Meier Estimate | 4 | 2019 | 860 | 0.310 |
Why?
|
Ultrasonography, Interventional | 4 | 2018 | 121 | 0.310 |
Why?
|
Ureteral Neoplasms | 3 | 2012 | 13 | 0.300 |
Why?
|
Penile Erection | 2 | 2017 | 22 | 0.300 |
Why?
|
Odds Ratio | 3 | 2017 | 678 | 0.300 |
Why?
|
Diffusion Magnetic Resonance Imaging | 6 | 2019 | 294 | 0.300 |
Why?
|
Recurrence | 6 | 2023 | 1139 | 0.300 |
Why?
|
Nuclear Proteins | 2 | 2014 | 696 | 0.290 |
Why?
|
Radiotherapy, Intensity-Modulated | 2 | 2019 | 173 | 0.280 |
Why?
|
Europe | 4 | 2020 | 309 | 0.280 |
Why?
|
Perioperative Care | 2 | 2019 | 161 | 0.280 |
Why?
|
Neoplasm Metastasis | 8 | 2014 | 1056 | 0.270 |
Why?
|
Cryptorchidism | 1 | 2005 | 11 | 0.270 |
Why?
|
Genital Neoplasms, Male | 1 | 2005 | 11 | 0.270 |
Why?
|
Kidney Failure, Chronic | 1 | 2010 | 509 | 0.260 |
Why?
|
Blood Loss, Surgical | 2 | 2016 | 112 | 0.260 |
Why?
|
Genetic Testing | 2 | 2020 | 535 | 0.260 |
Why?
|
Comorbidity | 3 | 2019 | 943 | 0.250 |
Why?
|
Kidney Function Tests | 4 | 2013 | 123 | 0.240 |
Why?
|
Sarcoma, Myeloid | 1 | 2004 | 15 | 0.240 |
Why?
|
Vascular Neoplasms | 1 | 2004 | 19 | 0.240 |
Why?
|
Image Interpretation, Computer-Assisted | 5 | 2018 | 663 | 0.240 |
Why?
|
Fructose | 1 | 2004 | 35 | 0.240 |
Why?
|
Urinary Calculi | 1 | 2004 | 46 | 0.240 |
Why?
|
Analysis of Variance | 6 | 2014 | 912 | 0.240 |
Why?
|
Length of Stay | 3 | 2016 | 702 | 0.240 |
Why?
|
Radiotherapy | 2 | 2016 | 328 | 0.240 |
Why?
|
Electrochemotherapy | 3 | 2018 | 4 | 0.230 |
Why?
|
Preoperative Care | 5 | 2019 | 397 | 0.230 |
Why?
|
Registries | 3 | 2019 | 702 | 0.230 |
Why?
|
Risk | 2 | 2015 | 674 | 0.230 |
Why?
|
Emphysema | 1 | 2003 | 22 | 0.230 |
Why?
|
Urologists | 1 | 2023 | 24 | 0.230 |
Why?
|
Penis | 1 | 2003 | 57 | 0.230 |
Why?
|
Chemoembolization, Therapeutic | 1 | 2003 | 36 | 0.230 |
Why?
|
Lymphadenopathy | 1 | 2023 | 17 | 0.230 |
Why?
|
Surveys and Questionnaires | 7 | 2022 | 2501 | 0.220 |
Why?
|
Health Surveys | 2 | 2015 | 239 | 0.220 |
Why?
|
Anticonvulsants | 1 | 2004 | 126 | 0.220 |
Why?
|
Antineoplastic Agents | 5 | 2019 | 2360 | 0.220 |
Why?
|
Magnetic Resonance Angiography | 1 | 2005 | 262 | 0.220 |
Why?
|
False Positive Reactions | 2 | 2015 | 216 | 0.210 |
Why?
|
Prostatic Neoplasms, Castration-Resistant | 1 | 2024 | 111 | 0.210 |
Why?
|
Magnetic Resonance Spectroscopy | 2 | 2014 | 318 | 0.210 |
Why?
|
Pulmonary Artery | 1 | 2004 | 306 | 0.210 |
Why?
|
Delphi Technique | 3 | 2019 | 80 | 0.210 |
Why?
|
Perception | 1 | 2023 | 168 | 0.210 |
Why?
|
Cause of Death | 2 | 2014 | 277 | 0.210 |
Why?
|
Angiomyolipoma | 1 | 2021 | 15 | 0.210 |
Why?
|
Lipoma | 1 | 2001 | 25 | 0.200 |
Why?
|
Primary Cell Culture | 3 | 2018 | 72 | 0.200 |
Why?
|
Medical Oncology | 3 | 2021 | 359 | 0.200 |
Why?
|
Ureteroscopy | 2 | 2012 | 37 | 0.200 |
Why?
|
Receptors, Androgen | 2 | 2018 | 113 | 0.200 |
Why?
|
Operative Time | 3 | 2016 | 127 | 0.200 |
Why?
|
Pulmonary Embolism | 1 | 2004 | 222 | 0.200 |
Why?
|
Hydronephrosis | 2 | 2011 | 31 | 0.200 |
Why?
|
Margins of Excision | 2 | 2022 | 39 | 0.190 |
Why?
|
Body Mass Index | 2 | 2014 | 770 | 0.190 |
Why?
|
Hypersensitivity | 1 | 2022 | 154 | 0.190 |
Why?
|
Adolescent | 7 | 2017 | 8981 | 0.180 |
Why?
|
Pelvis | 3 | 2019 | 95 | 0.180 |
Why?
|
Gene Regulatory Networks | 3 | 2018 | 296 | 0.180 |
Why?
|
Urinary Bladder | 3 | 2015 | 246 | 0.180 |
Why?
|
Propensity Score | 1 | 2020 | 136 | 0.180 |
Why?
|
Interdisciplinary Studies | 1 | 2019 | 20 | 0.180 |
Why?
|
Antineoplastic Agents, Immunological | 2 | 2019 | 185 | 0.180 |
Why?
|
Hyperthermia, Induced | 1 | 2020 | 73 | 0.180 |
Why?
|
Pathology, Molecular | 1 | 2019 | 34 | 0.180 |
Why?
|
Long Term Adverse Effects | 1 | 2019 | 6 | 0.180 |
Why?
|
Prostatic Hyperplasia | 2 | 2018 | 88 | 0.170 |
Why?
|
Mesothelioma | 1 | 2022 | 311 | 0.170 |
Why?
|
Urinalysis | 1 | 2019 | 33 | 0.170 |
Why?
|
Venae Cavae | 1 | 2019 | 14 | 0.170 |
Why?
|
Jordan | 1 | 2018 | 10 | 0.170 |
Why?
|
Linear Models | 4 | 2014 | 421 | 0.170 |
Why?
|
United States Food and Drug Administration | 1 | 2019 | 127 | 0.170 |
Why?
|
Survivors | 1 | 2020 | 226 | 0.170 |
Why?
|
Patients | 1 | 2019 | 100 | 0.170 |
Why?
|
Dissection | 2 | 2017 | 42 | 0.170 |
Why?
|
Pain, Procedural | 1 | 2018 | 3 | 0.160 |
Why?
|
Ultrasonography | 2 | 2013 | 695 | 0.160 |
Why?
|
Music Therapy | 1 | 2018 | 3 | 0.160 |
Why?
|
Journalism, Medical | 1 | 1998 | 6 | 0.160 |
Why?
|
Immunohistochemistry | 7 | 2013 | 1753 | 0.160 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2022 | 865 | 0.160 |
Why?
|
Neoplasms, Cystic, Mucinous, and Serous | 1 | 2018 | 16 | 0.160 |
Why?
|
Animals | 10 | 2014 | 26582 | 0.160 |
Why?
|
Quality Improvement | 2 | 2019 | 428 | 0.160 |
Why?
|
Emotions | 1 | 2022 | 341 | 0.160 |
Why?
|
Gadolinium | 1 | 2018 | 103 | 0.160 |
Why?
|
Employment | 1 | 1998 | 52 | 0.160 |
Why?
|
Transplantation Conditioning | 1 | 2020 | 373 | 0.160 |
Why?
|
Transcriptional Regulator ERG | 2 | 2015 | 15 | 0.160 |
Why?
|
Radiation Injuries | 1 | 2019 | 155 | 0.160 |
Why?
|
Pelvic Neoplasms | 1 | 2017 | 45 | 0.160 |
Why?
|
Cross-Sectional Studies | 2 | 2014 | 1621 | 0.160 |
Why?
|
Germ-Line Mutation | 1 | 2020 | 329 | 0.150 |
Why?
|
Models, Educational | 1 | 2017 | 50 | 0.150 |
Why?
|
Monitoring, Physiologic | 2 | 2009 | 268 | 0.150 |
Why?
|
Decision Support Techniques | 1 | 2019 | 160 | 0.150 |
Why?
|
Vascular Surgical Procedures | 1 | 2018 | 148 | 0.150 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2018 | 176 | 0.150 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2018 | 155 | 0.150 |
Why?
|
Hematologic Neoplasms | 1 | 2020 | 329 | 0.150 |
Why?
|
Urination Disorders | 2 | 2015 | 50 | 0.150 |
Why?
|
Urination | 1 | 2016 | 37 | 0.140 |
Why?
|
Positron-Emission Tomography | 1 | 2018 | 329 | 0.140 |
Why?
|
Hepatocyte Nuclear Factor 1 | 1 | 2016 | 30 | 0.140 |
Why?
|
Melanoma | 1 | 2020 | 459 | 0.140 |
Why?
|
RNA, Messenger | 3 | 2019 | 1981 | 0.140 |
Why?
|
Venous Thrombosis | 1 | 2019 | 243 | 0.140 |
Why?
|
Device Approval | 1 | 2015 | 13 | 0.140 |
Why?
|
Testis | 1 | 2016 | 152 | 0.140 |
Why?
|
Societies, Medical | 2 | 2017 | 572 | 0.140 |
Why?
|
Anxiety | 1 | 2018 | 287 | 0.140 |
Why?
|
Simulation Training | 1 | 2017 | 88 | 0.140 |
Why?
|
Regulatory Elements, Transcriptional | 1 | 2016 | 45 | 0.140 |
Why?
|
Spermatozoa | 1 | 2015 | 62 | 0.130 |
Why?
|
Cystadenoma | 1 | 2015 | 19 | 0.130 |
Why?
|
Corneal Injuries | 1 | 2015 | 10 | 0.130 |
Why?
|
Blood Transfusion | 1 | 2016 | 157 | 0.130 |
Why?
|
Creatinine | 2 | 2014 | 338 | 0.130 |
Why?
|
Selection Bias | 1 | 2015 | 37 | 0.130 |
Why?
|
Statistics, Nonparametric | 2 | 2013 | 307 | 0.130 |
Why?
|
Protein Precursors | 1 | 2015 | 143 | 0.130 |
Why?
|
Serine Endopeptidases | 1 | 2015 | 145 | 0.130 |
Why?
|
Probability | 3 | 2013 | 355 | 0.130 |
Why?
|
Gene Expression Regulation, Neoplastic | 4 | 2008 | 1197 | 0.130 |
Why?
|
Trans-Activators | 2 | 2015 | 429 | 0.130 |
Why?
|
Technology Assessment, Biomedical | 1 | 2014 | 27 | 0.120 |
Why?
|
Immunity, Innate | 1 | 2018 | 409 | 0.120 |
Why?
|
Sex Factors | 2 | 2015 | 1054 | 0.120 |
Why?
|
Child | 3 | 2020 | 6927 | 0.120 |
Why?
|
Anatomic Landmarks | 1 | 2014 | 31 | 0.120 |
Why?
|
Organ Sparing Treatments | 1 | 2014 | 38 | 0.120 |
Why?
|
Carrier Proteins | 2 | 2008 | 673 | 0.120 |
Why?
|
Hysterectomy | 1 | 2015 | 146 | 0.120 |
Why?
|
Interviews as Topic | 1 | 2015 | 319 | 0.120 |
Why?
|
Genomics | 2 | 2019 | 720 | 0.120 |
Why?
|
Mental Recall | 1 | 2015 | 159 | 0.120 |
Why?
|
MicroRNAs | 1 | 2018 | 534 | 0.120 |
Why?
|
Carcinoma, Small Cell | 1 | 2014 | 134 | 0.120 |
Why?
|
Lymphocele | 1 | 2013 | 6 | 0.120 |
Why?
|
Antigens, Neoplasm | 1 | 2015 | 325 | 0.120 |
Why?
|
Hematuria | 3 | 2022 | 49 | 0.120 |
Why?
|
Algorithms | 4 | 2019 | 1830 | 0.120 |
Why?
|
Peripheral Nerve Injuries | 1 | 2013 | 16 | 0.110 |
Why?
|
Mortality | 1 | 2014 | 149 | 0.110 |
Why?
|
Cell Proliferation | 2 | 2017 | 1578 | 0.110 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2019 | 1204 | 0.110 |
Why?
|
Confidence Intervals | 2 | 2013 | 229 | 0.110 |
Why?
|
Mannitol | 1 | 2012 | 49 | 0.110 |
Why?
|
Healthcare Disparities | 1 | 2017 | 371 | 0.110 |
Why?
|
ROC Curve | 4 | 2018 | 752 | 0.110 |
Why?
|
Activities of Daily Living | 1 | 2014 | 204 | 0.110 |
Why?
|
Social Media | 1 | 2014 | 79 | 0.110 |
Why?
|
Monte Carlo Method | 1 | 2013 | 185 | 0.110 |
Why?
|
Equipment Design | 1 | 2013 | 406 | 0.110 |
Why?
|
Chicago | 1 | 2016 | 1379 | 0.110 |
Why?
|
Reoperation | 2 | 2018 | 597 | 0.100 |
Why?
|
Advisory Committees | 1 | 2012 | 90 | 0.100 |
Why?
|
Urothelium | 1 | 2012 | 70 | 0.100 |
Why?
|
Clinical Decision-Making | 3 | 2019 | 257 | 0.100 |
Why?
|
Urography | 2 | 2009 | 45 | 0.100 |
Why?
|
Americas | 1 | 2011 | 19 | 0.100 |
Why?
|
Health Status | 1 | 2014 | 360 | 0.100 |
Why?
|
Mice, Nude | 3 | 2014 | 790 | 0.100 |
Why?
|
Patient Safety | 1 | 2014 | 212 | 0.100 |
Why?
|
Africa | 1 | 2011 | 98 | 0.100 |
Why?
|
Asia | 1 | 2011 | 95 | 0.100 |
Why?
|
Australia | 1 | 2011 | 99 | 0.100 |
Why?
|
Neovascularization, Pathologic | 2 | 2011 | 353 | 0.100 |
Why?
|
Cystectomy | 2 | 2010 | 102 | 0.100 |
Why?
|
Repressor Proteins | 1 | 2014 | 403 | 0.100 |
Why?
|
Mathematics | 1 | 2010 | 190 | 0.090 |
Why?
|
Depression | 1 | 2014 | 473 | 0.090 |
Why?
|
Physicians | 1 | 1998 | 673 | 0.090 |
Why?
|
Diagnosis, Differential | 4 | 2021 | 1565 | 0.090 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2023 | 2438 | 0.090 |
Why?
|
Proteins | 1 | 2015 | 777 | 0.090 |
Why?
|
Urinary Reservoirs, Continent | 1 | 2010 | 14 | 0.090 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2003 | 381 | 0.090 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2013 | 332 | 0.090 |
Why?
|
Trauma, Nervous System | 1 | 2009 | 6 | 0.090 |
Why?
|
Ejaculation | 1 | 2009 | 9 | 0.090 |
Why?
|
Internship and Residency | 2 | 2017 | 1004 | 0.090 |
Why?
|
Urine | 1 | 2010 | 90 | 0.090 |
Why?
|
Medical Illustration | 1 | 2009 | 16 | 0.090 |
Why?
|
Obesity | 2 | 2014 | 963 | 0.090 |
Why?
|
Smoking | 1 | 2014 | 609 | 0.090 |
Why?
|
Gene Expression Profiling | 4 | 2018 | 1384 | 0.090 |
Why?
|
Calreticulin | 1 | 2009 | 13 | 0.090 |
Why?
|
Credentialing | 1 | 2009 | 13 | 0.090 |
Why?
|
Urinary Diversion | 1 | 2010 | 42 | 0.090 |
Why?
|
Postoperative Period | 3 | 2015 | 303 | 0.090 |
Why?
|
Socioeconomic Factors | 1 | 2012 | 567 | 0.090 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2014 | 350 | 0.090 |
Why?
|
Radiographic Image Enhancement | 1 | 2012 | 462 | 0.090 |
Why?
|
Residence Characteristics | 1 | 2011 | 197 | 0.090 |
Why?
|
Living Donors | 1 | 2012 | 339 | 0.090 |
Why?
|
Nephrons | 1 | 2009 | 18 | 0.090 |
Why?
|
Dutasteride | 1 | 2009 | 5 | 0.090 |
Why?
|
Azasteroids | 1 | 2009 | 5 | 0.090 |
Why?
|
3-Oxo-5-alpha-Steroid 4-Dehydrogenase | 1 | 2009 | 9 | 0.090 |
Why?
|
Cell Line, Tumor | 4 | 2009 | 2426 | 0.090 |
Why?
|
Validation Studies as Topic | 1 | 2009 | 16 | 0.090 |
Why?
|
Fascia | 1 | 2009 | 30 | 0.090 |
Why?
|
Bacteriochlorophylls | 1 | 2008 | 1 | 0.080 |
Why?
|
Multicenter Studies as Topic | 1 | 2009 | 159 | 0.080 |
Why?
|
Proto-Oncogene Proteins c-ets | 1 | 2008 | 25 | 0.080 |
Why?
|
Gene Expression Regulation | 4 | 2018 | 1920 | 0.080 |
Why?
|
Primary Prevention | 1 | 2009 | 85 | 0.080 |
Why?
|
Urologic Surgical Procedures | 1 | 2009 | 146 | 0.080 |
Why?
|
Prostatic Secretory Proteins | 1 | 2007 | 1 | 0.080 |
Why?
|
Seminal Plasma Proteins | 1 | 2007 | 1 | 0.080 |
Why?
|
Neoplastic Stem Cells | 1 | 2009 | 143 | 0.080 |
Why?
|
Salivary Proteins and Peptides | 1 | 2007 | 5 | 0.080 |
Why?
|
Overweight | 1 | 2008 | 118 | 0.080 |
Why?
|
Catheter Ablation | 3 | 2016 | 233 | 0.080 |
Why?
|
Gene Rearrangement | 1 | 2008 | 170 | 0.080 |
Why?
|
Swine | 1 | 2008 | 555 | 0.080 |
Why?
|
Dioxygenases | 1 | 2007 | 74 | 0.080 |
Why?
|
Radiotherapy, Conformal | 1 | 2007 | 83 | 0.070 |
Why?
|
Chronic Disease | 1 | 2010 | 971 | 0.070 |
Why?
|
Survival | 1 | 2006 | 21 | 0.070 |
Why?
|
Neoadjuvant Therapy | 2 | 2019 | 318 | 0.070 |
Why?
|
Prednisone | 2 | 2024 | 258 | 0.070 |
Why?
|
BCG Vaccine | 1 | 2006 | 31 | 0.070 |
Why?
|
Gene Fusion | 2 | 2021 | 38 | 0.070 |
Why?
|
Carcinoma in Situ | 1 | 2006 | 53 | 0.070 |
Why?
|
Reproducibility of Results | 4 | 2014 | 2705 | 0.070 |
Why?
|
Kidney Transplantation | 1 | 2012 | 849 | 0.070 |
Why?
|
Thromboembolism | 1 | 2006 | 119 | 0.070 |
Why?
|
Immunocompromised Host | 1 | 2006 | 140 | 0.070 |
Why?
|
Adjuvants, Immunologic | 1 | 2006 | 167 | 0.070 |
Why?
|
Evidence-Based Medicine | 1 | 2008 | 429 | 0.070 |
Why?
|
Steroids | 1 | 2006 | 177 | 0.070 |
Why?
|
Kinetics | 1 | 2007 | 1513 | 0.060 |
Why?
|
Transplantation, Heterologous | 1 | 2006 | 363 | 0.060 |
Why?
|
Costs and Cost Analysis | 1 | 2005 | 153 | 0.060 |
Why?
|
Cystitis | 1 | 2004 | 13 | 0.060 |
Why?
|
Cardiovascular Diseases | 1 | 2011 | 827 | 0.060 |
Why?
|
Cell Nucleolus | 1 | 2004 | 23 | 0.060 |
Why?
|
Abiraterone Acetate | 1 | 2024 | 11 | 0.060 |
Why?
|
Castration | 1 | 2024 | 41 | 0.060 |
Why?
|
Cell Cycle | 1 | 2006 | 502 | 0.060 |
Why?
|
Daunorubicin | 1 | 2004 | 78 | 0.060 |
Why?
|
Plasma Cells | 1 | 2004 | 80 | 0.060 |
Why?
|
Coitus | 1 | 2003 | 20 | 0.060 |
Why?
|
Referral and Consultation | 1 | 2006 | 328 | 0.060 |
Why?
|
Rupture | 1 | 2003 | 63 | 0.060 |
Why?
|
Paclitaxel | 1 | 2005 | 460 | 0.060 |
Why?
|
Severity of Illness Index | 1 | 2009 | 1801 | 0.060 |
Why?
|
Cytarabine | 1 | 2004 | 218 | 0.060 |
Why?
|
Methotrexate | 1 | 2004 | 249 | 0.060 |
Why?
|
Carcinoma | 1 | 2006 | 436 | 0.060 |
Why?
|
Urinary Fistula | 1 | 2002 | 7 | 0.060 |
Why?
|
Vascular Fistula | 1 | 2002 | 12 | 0.060 |
Why?
|
Genes, p53 | 1 | 2003 | 109 | 0.060 |
Why?
|
Fatal Outcome | 1 | 2003 | 293 | 0.060 |
Why?
|
Iliac Artery | 1 | 2002 | 35 | 0.060 |
Why?
|
Diet, Vegan | 1 | 2022 | 1 | 0.060 |
Why?
|
Suture Techniques | 1 | 2003 | 135 | 0.050 |
Why?
|
Abdominal Pain | 1 | 2004 | 137 | 0.050 |
Why?
|
Fat Necrosis | 1 | 2002 | 6 | 0.050 |
Why?
|
Testosterone | 1 | 2024 | 271 | 0.050 |
Why?
|
Mice | 4 | 2014 | 11352 | 0.050 |
Why?
|
Acute Disease | 1 | 2004 | 826 | 0.050 |
Why?
|
Colonic Diseases | 1 | 2002 | 65 | 0.050 |
Why?
|
Life Style | 1 | 2022 | 189 | 0.050 |
Why?
|
Seizures | 1 | 2004 | 297 | 0.050 |
Why?
|
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2021 | 54 | 0.050 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2018 | 879 | 0.050 |
Why?
|
Chromatin | 1 | 2004 | 380 | 0.050 |
Why?
|
Urethra | 1 | 2002 | 113 | 0.050 |
Why?
|
Calcinosis | 1 | 2002 | 224 | 0.050 |
Why?
|
Oligonucleotide Array Sequence Analysis | 3 | 2008 | 689 | 0.050 |
Why?
|
Muscle, Smooth | 1 | 2002 | 354 | 0.050 |
Why?
|
Organ Size | 1 | 2021 | 364 | 0.050 |
Why?
|
Canada | 1 | 2020 | 204 | 0.050 |
Why?
|
Cells, Cultured | 2 | 2016 | 2818 | 0.050 |
Why?
|
Stents | 1 | 2002 | 377 | 0.050 |
Why?
|
Biopsy, Large-Core Needle | 1 | 2019 | 14 | 0.050 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2021 | 302 | 0.040 |
Why?
|
Radiologic Health | 1 | 2019 | 2 | 0.040 |
Why?
|
Endpoint Determination | 1 | 2019 | 60 | 0.040 |
Why?
|
San Francisco | 1 | 2019 | 21 | 0.040 |
Why?
|
Kidney Calculi | 1 | 2003 | 339 | 0.040 |
Why?
|
Education | 1 | 2019 | 58 | 0.040 |
Why?
|
Diet | 1 | 2022 | 443 | 0.040 |
Why?
|
Support Vector Machine | 1 | 2019 | 25 | 0.040 |
Why?
|
History, 20th Century | 1 | 2020 | 312 | 0.040 |
Why?
|
CCAAT-Enhancer-Binding Protein-beta | 1 | 2018 | 12 | 0.040 |
Why?
|
Cell Line | 2 | 2018 | 2468 | 0.040 |
Why?
|
Core Binding Factor Alpha 2 Subunit | 1 | 2018 | 52 | 0.040 |
Why?
|
Anticoagulants | 1 | 2022 | 408 | 0.040 |
Why?
|
Unnecessary Procedures | 1 | 2019 | 51 | 0.040 |
Why?
|
Health Services Accessibility | 1 | 2022 | 394 | 0.040 |
Why?
|
Ploidies | 1 | 2018 | 40 | 0.040 |
Why?
|
Mexico | 1 | 2018 | 67 | 0.040 |
Why?
|
PAX2 Transcription Factor | 1 | 2018 | 6 | 0.040 |
Why?
|
Disease Susceptibility | 1 | 2019 | 193 | 0.040 |
Why?
|
DEAD Box Protein 58 | 1 | 2018 | 11 | 0.040 |
Why?
|
Poly I-C | 1 | 2018 | 16 | 0.040 |
Why?
|
Toll-Like Receptor 3 | 1 | 2018 | 9 | 0.040 |
Why?
|
Intention to Treat Analysis | 1 | 2018 | 72 | 0.040 |
Why?
|
Career Mobility | 1 | 1998 | 31 | 0.040 |
Why?
|
Patient Reported Outcome Measures | 1 | 2019 | 166 | 0.040 |
Why?
|
Heredity | 1 | 2017 | 19 | 0.040 |
Why?
|
Quality Control | 1 | 2018 | 117 | 0.040 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2004 | 763 | 0.040 |
Why?
|
Epithelium | 1 | 2018 | 319 | 0.040 |
Why?
|
Radiation Oncology | 1 | 2019 | 119 | 0.040 |
Why?
|
Proto-Oncogene Proteins | 1 | 2021 | 645 | 0.040 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2018 | 348 | 0.040 |
Why?
|
Patient Preference | 1 | 2018 | 105 | 0.040 |
Why?
|
Sequence Analysis, RNA | 1 | 2018 | 217 | 0.040 |
Why?
|
Cell Transformation, Neoplastic | 2 | 2014 | 427 | 0.040 |
Why?
|
Molecular Targeted Therapy | 1 | 2019 | 266 | 0.040 |
Why?
|
Recovery of Function | 2 | 2010 | 272 | 0.040 |
Why?
|
Clinical Competence | 2 | 2015 | 751 | 0.040 |
Why?
|
Controlled Clinical Trials as Topic | 1 | 2016 | 24 | 0.040 |
Why?
|
Age of Onset | 1 | 2017 | 310 | 0.040 |
Why?
|
Career Choice | 1 | 1998 | 139 | 0.040 |
Why?
|
Pain Measurement | 1 | 2018 | 321 | 0.040 |
Why?
|
Social Behavior | 1 | 2019 | 294 | 0.040 |
Why?
|
Ligands | 1 | 2018 | 433 | 0.040 |
Why?
|
Anti-Inflammatory Agents | 2 | 2012 | 339 | 0.040 |
Why?
|
Psychiatric Status Rating Scales | 1 | 2018 | 487 | 0.040 |
Why?
|
Sperm Maturation | 1 | 2015 | 1 | 0.030 |
Why?
|
Gene Ontology | 1 | 2015 | 34 | 0.030 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2009 | 458 | 0.030 |
Why?
|
Pilot Projects | 1 | 2018 | 839 | 0.030 |
Why?
|
Self Report | 1 | 2017 | 288 | 0.030 |
Why?
|
Chromatin Immunoprecipitation | 1 | 2016 | 133 | 0.030 |
Why?
|
Pedigree | 1 | 2017 | 966 | 0.030 |
Why?
|
Molecular Sequence Annotation | 1 | 2015 | 67 | 0.030 |
Why?
|
Preoperative Period | 1 | 2015 | 91 | 0.030 |
Why?
|
Learning Curve | 1 | 2015 | 18 | 0.030 |
Why?
|
Diagnostic Imaging | 1 | 2019 | 469 | 0.030 |
Why?
|
Keratin-8 | 1 | 2014 | 1 | 0.030 |
Why?
|
Clusterin | 1 | 2014 | 13 | 0.030 |
Why?
|
Organ Specificity | 1 | 2015 | 258 | 0.030 |
Why?
|
London | 1 | 2014 | 16 | 0.030 |
Why?
|
Forearm | 1 | 1994 | 32 | 0.030 |
Why?
|
Cell Membrane Permeability | 1 | 2014 | 119 | 0.030 |
Why?
|
Apoptosis | 3 | 2007 | 1683 | 0.030 |
Why?
|
Cryotherapy | 1 | 2014 | 29 | 0.030 |
Why?
|
HIV Infections | 1 | 2003 | 772 | 0.030 |
Why?
|
Ultrasonic Therapy | 1 | 2014 | 32 | 0.030 |
Why?
|
Cell Polarity | 1 | 2014 | 115 | 0.030 |
Why?
|
Computer Simulation | 1 | 2018 | 1078 | 0.030 |
Why?
|
Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2014 | 25 | 0.030 |
Why?
|
Electroporation | 1 | 2014 | 55 | 0.030 |
Why?
|
Ubiquitination | 1 | 2014 | 67 | 0.030 |
Why?
|
Heterografts | 1 | 2014 | 98 | 0.030 |
Why?
|
Critical Pathways | 1 | 2013 | 35 | 0.030 |
Why?
|
Models, Anatomic | 1 | 2013 | 91 | 0.030 |
Why?
|
Gene Knockdown Techniques | 1 | 2014 | 236 | 0.030 |
Why?
|
Discriminant Analysis | 1 | 2013 | 66 | 0.030 |
Why?
|
Nitric Oxide | 1 | 1994 | 278 | 0.030 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2014 | 165 | 0.030 |
Why?
|
Internationality | 1 | 2012 | 69 | 0.030 |
Why?
|
Checklist | 1 | 2013 | 57 | 0.030 |
Why?
|
Membrane Glycoproteins | 1 | 2014 | 428 | 0.030 |
Why?
|
Computational Biology | 1 | 2016 | 528 | 0.030 |
Why?
|
Observer Variation | 1 | 2014 | 602 | 0.030 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2016 | 456 | 0.030 |
Why?
|
Postoperative Care | 1 | 2013 | 221 | 0.030 |
Why?
|
Area Under Curve | 1 | 2013 | 334 | 0.030 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2020 | 2357 | 0.030 |
Why?
|
Attitude of Health Personnel | 1 | 2017 | 636 | 0.030 |
Why?
|
Carcinogenesis | 1 | 2014 | 195 | 0.030 |
Why?
|
HEK293 Cells | 1 | 2014 | 615 | 0.030 |
Why?
|
Health Care Surveys | 1 | 2012 | 278 | 0.030 |
Why?
|
Mice, Inbred BALB C | 1 | 2014 | 1047 | 0.030 |
Why?
|
Muscles | 1 | 2012 | 194 | 0.030 |
Why?
|
Immunoenzyme Techniques | 1 | 2011 | 303 | 0.030 |
Why?
|
Antioxidants | 1 | 2012 | 223 | 0.030 |
Why?
|
Stress, Psychological | 1 | 1994 | 313 | 0.030 |
Why?
|
Tissue Culture Techniques | 1 | 2011 | 79 | 0.030 |
Why?
|
Phenotype | 1 | 2017 | 2378 | 0.020 |
Why?
|
Transcription, Genetic | 1 | 2016 | 1135 | 0.020 |
Why?
|
Cytodiagnosis | 1 | 2011 | 42 | 0.020 |
Why?
|
Patient Discharge | 1 | 2013 | 300 | 0.020 |
Why?
|
Ureter | 1 | 2011 | 92 | 0.020 |
Why?
|
Constriction | 1 | 2009 | 27 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2010 | 364 | 0.020 |
Why?
|
Cell Differentiation | 1 | 2015 | 1458 | 0.020 |
Why?
|
Fibrosis | 1 | 2010 | 203 | 0.020 |
Why?
|
Digital Rectal Examination | 1 | 2008 | 7 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 1 | 2017 | 2271 | 0.020 |
Why?
|
Observation | 1 | 2008 | 37 | 0.020 |
Why?
|
Trypsin Inhibitor, Kazal Pancreatic | 1 | 2008 | 5 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2012 | 1961 | 0.020 |
Why?
|
Education, Medical, Continuing | 1 | 2009 | 107 | 0.020 |
Why?
|
Tissue Array Analysis | 1 | 2008 | 124 | 0.020 |
Why?
|
Down-Regulation | 1 | 2009 | 504 | 0.020 |
Why?
|
Protein Structure, Tertiary | 1 | 2009 | 736 | 0.020 |
Why?
|
Lung Diseases | 1 | 2009 | 263 | 0.020 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2007 | 67 | 0.020 |
Why?
|
RNA Interference | 1 | 2008 | 369 | 0.020 |
Why?
|
Metals | 1 | 2007 | 90 | 0.020 |
Why?
|
Administration, Intravesical | 1 | 2006 | 33 | 0.020 |
Why?
|
Transfection | 1 | 2008 | 896 | 0.020 |
Why?
|
RNA, Small Interfering | 1 | 2008 | 547 | 0.020 |
Why?
|
Education, Medical, Graduate | 1 | 2009 | 369 | 0.020 |
Why?
|
Mutation | 2 | 2009 | 3968 | 0.020 |
Why?
|
Neoplasm Transplantation | 1 | 2005 | 391 | 0.020 |
Why?
|
Models, Biological | 1 | 2011 | 1749 | 0.020 |
Why?
|
Eosinophilia | 1 | 2004 | 84 | 0.010 |
Why?
|
Neoplasms, Experimental | 1 | 2005 | 269 | 0.010 |
Why?
|
Cystitis, Interstitial | 1 | 2004 | 53 | 0.010 |
Why?
|
Protein Binding | 1 | 2007 | 1456 | 0.010 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2005 | 276 | 0.010 |
Why?
|
Signal Transduction | 1 | 2014 | 3241 | 0.010 |
Why?
|
Urologic Surgical Procedures, Male | 1 | 2002 | 11 | 0.010 |
Why?
|
Rats | 1 | 2009 | 3990 | 0.010 |
Why?
|
Cell Survival | 1 | 2005 | 969 | 0.010 |
Why?
|
Shock | 1 | 2002 | 42 | 0.010 |
Why?
|
Gene Silencing | 1 | 2003 | 172 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2008 | 1208 | 0.010 |
Why?
|
Autopsy | 1 | 2002 | 116 | 0.010 |
Why?
|
Transcription Factors | 1 | 2008 | 1565 | 0.010 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2002 | 275 | 0.010 |
Why?
|
omega-N-Methylarginine | 1 | 1994 | 17 | 0.010 |
Why?
|
Atropine | 1 | 1994 | 59 | 0.010 |
Why?
|
Vasodilation | 1 | 1994 | 96 | 0.010 |
Why?
|
Arginine | 1 | 1994 | 136 | 0.010 |
Why?
|
Regional Blood Flow | 1 | 1994 | 197 | 0.010 |
Why?
|
Blood Flow Velocity | 1 | 1994 | 197 | 0.010 |
Why?
|